SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau completed enrollment in its ReSTART pivotal trial (88…

Alpha Tau Medical Ltd. · PRESS-RELEASE filed May 8, 2026 at 09:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 8, 2026 at 09:00 ET

Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key step toward FDA PMA approval. The company has Breakthrough Device Designation and submitted the first PMA module in January 2026. This milestone de-risks the regulatory pathway but approval and commercialization remain uncertain.

  • Completed enrollment of 88 patients in ReSTART pivotal trial for recurrent cSCC.
  • First U.S. pivotal study for Alpha Tau to complete enrollment.
  • Alpha DaRT has FDA Breakthrough Device Designation for this indication.
  • First module of modular PMA application submitted in January 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access